NASDAQ:VCEL - Vericel Stock Price, Forecast & News

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel Corp (NASDAQ:VCEL) posted its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.09. The biotechnology company had revenue of $30.50 million for the quarter, compared to analyst estimates of $26.84 million. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The firm's revenue for the quarter was up 35.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.02) earnings per share. View Vericel's Earnings History.

Vericel is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Vericel.

4 analysts have issued 12 month price objectives for Vericel's shares. Their forecasts range from $17.92 to $32.00. On average, they expect Vericel's stock price to reach $23.23 in the next twelve months. This suggests a possible upside of 38.1% from the stock's current price. View Analyst Price Targets for Vericel.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.

News stories about VCEL stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vericel earned a news impact score of -4.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Vericel.

Some companies that are related to Vericel include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Coherus Biosciences (CHRS) and Orchard Therapeutics (ORTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Momo (MOMO), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Amarin (AMRN), Dynavax Technologies (DVAX), NVIDIA (NVDA), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX) and Verastem (VSTM).

Vericel's stock is owned by many different of institutional and retail investors. Top institutional investors include Calamos Advisors LLC (0.48%), Roubaix Capital LLC (0.15%), Ingalls & Snyder LLC (0.13%), Falcon Point Capital LLC (0.13%), Conestoga Capital Advisors LLC (0.10%) and Campbell & CO Investment Adviser LLC (0.07%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Falcon Point Capital LLC and Ingalls & Snyder LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, Michael Halpin and Steven C Gilman. View Insider Buying and Selling for Vericel.

VCEL stock was purchased by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Campbell & CO Investment Adviser LLC and Conestoga Capital Advisors LLC. View Insider Buying and Selling for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $16.82.

Vericel has a market capitalization of $751.69 million and generates $90.86 million in revenue each year. The biotechnology company earns $-8,140,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Vericel employs 216 workers across the globe.View Additional Information About Vericel.

The official website for Vericel is http://www.vcel.com/.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]